Women in Pharma and MassBio Discuss Gender Diversity

Posted by Kathy Marini
On December 20, 2018

The Chapter’s Women in Pharma (WIP) group recently hosted “Bridging the Gender Diversity Gap” at the Alexion facility in the Seaport District, with audience participation one of the main drivers of the event. Featured was Liz Steele, MassBio VP of Programs and Global Affairs, who reviewed the MassBio report on gender diversity and outlined the […]

Entrada Launches with $59m in Venture Capital

Posted by ISPE Boston
On December 18, 2018

Entrada Therapeutics has raised $59 million in a Series A financing co-led by 5AM Ventures and MPM Capital, along with Roche Venture Fund, MRL Ventures Fund and Agent Capital. Entrada was funded and incubated within 5AM’s 4:59 Initiative via a seed investment by 5AM Ventures, Roche Venture Fund and MRLV. Entrada’s proprietary intracellular biologics platform has […]

PARP Inhibitors May Offer New Treatment Options for Cancer Patients

Posted by ISPE Boston
On December 12, 2018

PARP, or poly(ADP-ribose) polymerase, is a family of proteins that helps repair damaged DNA in cells. A PARP inhibitor may prevent cancer cells from repairing their damaged DNA, which can cause cancer cells to die. This may slow the return or progress of cancer. BRCA is a gene that is linked to increased risk for […]

GSK to Acquire TESARO for $5.1 Billion

Posted by ISPE Boston
On December 12, 2018

TESARO, an oncology-focused company based in Waltham, and GlaxoSmithKline (GSK) have announced that they have entered into a definitive agreement by which GSK will acquire TESARO for an aggregate cash consideration of approximately $5.1 billion. The proposed transaction significantly strengthens GSK’s pharmaceutical business, accelerating the build of GSK’s pipeline and commercial capability in oncology. TESARO […]

Panelists Shed Light on Manufacturing Facilities for Novel Therapeutics

Posted by ISPE Boston
On December 12, 2018

The Novel Therapeutics panel discussion on December 6th was a great success, with nearly 80 attendees and a strong panel of experts consisting of Stacy Price of Ziopharm, Bankim Patel of Moderna, John Dougherty of DPS, consultant Lance Weed and moderator Jeffrey Kent of DPS. The design of manufacturing facilities for novel therapeutics requires careful […]

Volunteers Meet for First Committee Meeting of Product Show 2019

Posted by ISPE Boston
On December 12, 2018

The first committee meeting of the 2019 Product Show took place on Monday, December 3 at Flatbread’s Pizza & Bowling in Brighton, MA. This first meeting is an opportunity for volunteers both new and old to meet and to go over what’s in store for the coming planning year. This year, the Product Show Committee […]

Chapter Member Anniversaries: November 2018

Posted by ISPE Boston
On December 5, 2018

Please congratulate the following members celebrating milestone anniversaries in November 2018. Their dedication to ISPE, the Boston Area Chapter and the industry is applauded! Over Twenty Years Charles H. Brown, II, MS, Retired Thomas G. Larkin, Jr., Massachusetts Biologic Laboratories Pasquale M. Sacco, Highland Advisors LLC Twenty Years Donald A. Ross, BSCE, MSCE, […]

Welcome New Members!

Posted by ISPE Boston
On December 5, 2018

We would like to introduce the Members who joined ISPE in November 2018, welcome them to the Chapter and encourage them (and all of our members) to take advantage of the many professional development, networking and information resources available through ISPE. Fellow ISPE members are a terrific resource for help with everyday professional challenges. And […]

New Triple-Drug Therapy from Vertex Shows Promise

Posted by ISPE Boston
On November 30, 2018

Vertex Pharmaceuticals has announced that treatment with the triple combination of the next-generation corrector VX-659, tezacaftor and ivacaftor resulted in statistically significant improvements in lung function in two Phase 3 studies in people with cystic fibrosis (CF). Vertex also today announced that enrollment is complete for the two Phase 3 studies of the triple combination […]

Designing, Building & Operating Manufacturing Facilities for Novel Therapeutics

Posted by ISPE Boston
On November 29, 2018

Design of manufacturing facilities for the production of novel therapeutics requires careful planning and consideration of a myriad of factors, such as throughput, biosafety level, product segregation and contamination control, regulatory environment, time to market, and tech transfer challenges. It is a complex mix of elements and requires a project team that can move quickly […]

Page 89 of 117«‹87 888990 91 ›»